This filing contains only routine board and leadership changes with no financial or operational catalysts. Monitor upcoming quarterly results for any strategic shifts under the new chair/CEO structure.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $8.00entry
- T+1 · 5mo ago +3.50%α +3.63% · $8.28
- T+5 · 4mo ago +11.75%α +11.49% · $8.94
- T+20 · 4mo ago +4.75%α +6.94% · $8.38
- T+60 · 8w ago +11.88%α +8.92% · $8.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xeris Biopharma announced routine board governance changes: CEO John Shannon was appointed Chair of the Board, Marla Persky transitioned to Lead Independent Director, and Nerissa Kreher, M.D., was added as an independent director. The board expanded from seven to eight members. No financial data or operational updates were provided.
Key Facts
- Board expanded from 7 to 8 members with the appointment of Nerissa Kreher, M.D., effective July 1, 2026
- CEO John Shannon appointed Chair of the Board, effective July 1, 2026
- Marla Persky designated as Lead Independent Director, effective July 1, 2026
- Dr. Kreher received an initial equity award with aggregate grant date fair value of approximately $450,000
- Dr. Kreher is independent under Nasdaq listing standards and has extensive biotech CMO experience
Financial Impact
No financial impact; routine governance changes with no material financial data disclosed
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001867096-26-000048 |
| Exhibit: exh991boardappointmentpres.htm | 0001867096-26-000048 |
| Document: 0001867096-26-000048-index-headers.html | 0001867096-26-000048 |
| Document: 0001867096-26-000048-index.html | 0001867096-26-000048 |
| Document: 0001867096-26-000048.txt | 0001867096-26-000048 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers